Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Oxford
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Willing and able to give informed consent, can communicate in English
Age between 18 and 65 years inclusive
Live in England
BMI ≥27 kg/m2 or higher (adjusted to ≥25 kg/m2 for people of Black, Asian and minority ethnic origin)
Diagnosed with T2D within 6 years prior to the day of screening
Global EDE-Q scores ≥2.67
To have an HbA1c taken in the last 12 months
Latest HbA1c ≥43 mmol/mol (6.1%) and ≤87 mmol/mol (10%) if on diabetes medication OR latest hbA1c ≥ 48 mmol/mol (6.5%) and ≤87 mmol/mol (10%), if not on diabetes medication.
If diagnosed with type 2 diabetes more than 1 year since day of screening, the participant must have attended their GP surgery for monitoring/ diabetes review when last offered
Commit to continue annual reviews with their GP, even if T2D remission is achieved
You may not be if
The participant must not enter the study if ANY of the following apply:
Current or previous clinical diagnosis of an eating disorder
Combination of EDE-Q ≥4 AND a CIA score ≥16 at screening
Currently participating in a structured weight loss programme or self-reporting that they have lost \>10% of their body weight in the last 3 months
Insulin use
Known kidney disease of stage 3/4/5 or eGFR \<60 mls/min/1.73 m2 within the last 12 months
Active substance use disorder
Active cancer other than skin cancer
Known proliferative retinopathy that has not been treated
Porphyria
Undergone or is awaiting bariatric surgery
Myocardial infarction or stroke within previous 6 months
Severe heart failure defined as equivalent to the New York Heart Association (NYHA) grade 3 or 4
Active liver disease (not including non-alcoholic fatty liver disease)
Pregnant, breastfeeding, or planning to become pregnant during the course of the study
Soy or milk or fish allergy, lactose intolerance, or following a vegan diet
People currently participating in another study or clinical trial of a CTIMP/non-CTIMP
Clareo Health | ARIADNE: A Study of Weight Loss for Diabetes Treatment and Wellbeing
